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Abstracts / Osteoarthritis and Cartilage 28 (2020) S86eS527S472anterior part of the cartilage, the percentage of MMP-13-positive cells in
the posterior part of the cartilage was significantly higher for the ACL-T/
Ex group than for the CAJM/Ex group (p¼0.02) (Fig. 3C).
Conclusions: Previous studies reported that exercise alone could delay
the progress of OA. However, our present Results indicate that the
internal environment of the joint strongly modulates the effect of
exercise, sometimes completely canceling the benefit. In other words,
when prescribing exercise, we need to consider the internal environ-
ment of the knee joint.In the clinical setting, these findings may trans-
late in the need to consider an intervention to correct abnormal joint
movement before prescribing physical exercise in the treatment of OA.706
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Purpose: The aim of this study was to investigate the effects of a 6-
month intervention with an Olive Leaf Extract (OLE) standardized for
oleuropein content on knee functionality and biomarkers of bone/car-
tilage metabolism and inflammation.
Methods: The study was a randomized, double-blind, placebo-con-
trolled, multi-centric trial of 124 subjects with mild knee pain or
mobility issues. Subjects were randomized equally to receive twice a
day one capsule of either maltodextrin (control treatment, CT) or 125-
mg OLE (BonoliveTM, an Olive Leaf Extract containing 50 mg of Oleur-
opein) for 6 months. The co-primary endpoints were Knee injury and
Osteoarthritis Outcome Score (KOOS) using a self-administered ques-
tionnaire and serum Coll2-1NO2 specific biomarker of cartilage deg-
radation. The secondary endpoints were each of the five sub-scales of
the KOOS questionnaire, Knee pain VAS score at rest and at walking,
OARSI core set of performance-based tests and serum biomarkers
(Coll2-1, MPO, CTX1, osteocalcin, PGE2 and Vplex cytokines assay in
serum) and concentration of Oleuropein’s metabolites in urine.
Results: Primary (global KOOS score, biomarker Coll2-1 NO2) and
secondary endpoints (the five subscales of the KOOS score) improved
time dependently in both groups. OLE treatment showed significantly
elevated urinary oleuropein metabolites (oleuropein aglycone,
hydroxytyrosol, homovanillyl alcohol and isomer of homovanillyl
alcohol), and was well tolerated without significant differences in
number of subjects with adverse events. At 6 months, OLE group
showed a higher global KOOS score compared to placebo (treatment
difference ¼ 3.73; 95% CI ¼ [-4.08;11.54]; p ¼ 0.34), without significant
changes of inflammatory and cartilage remodeling biomarkers. Sub-
group analyses demonstrated a large and significant treatment effect of
OLE in subjects with high walking pain at baseline (14.4; 95% CI ¼
[1.19;27.63], p¼0.03). This was observed at 6 months for the global
KOOS score and each different subscale and for pain at walking
(-23.07;95% CI ¼ [-41.8; -4.2]; p¼0.02). These treatment effects at 6
months were significant for KOOS score as well as for the subscales Pain
and QoL and the pain at walking.
Conclusions: OLE was not effective on joint discomfort in people with
low to moderate pain at baseline but significantly benefited subjects
with high pain at treatment initiation. As oleuropein is well-tolerated,
OLE can be used to relieve knee joint pain and enhance mobility in
subjects with articular pain the most painful subjects.
